Date: 2015-07-29
Type of information: Collaboration agreement
Compound: compounds including BPS-804, BCT-197 and BGS-649
Company: Novartis (Switzerland) Mereo BioPharma (UK)
Therapeutic area: Bone diseases - Endocrinological diseases - Hormonal diseases - Inflammatory diseases - Pulmonary diseases - Rare diseases - Respiratory diseases
Type agreement: collaboration
Action mechanism:
Disease: improvement of bone density in brittle bone syndrome, acute exacerbations in COPD, normalization of testosterone levels in obese men with hypogonadotrophic hypogonadism
Details: * On July 29, 2015, Novartis announced a swap of clinical assets for equity with Mereo BioPharma. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales. Mereo is a recently formed specialty biopharmaceutical company based in the UK who focuses on the acquisition and development of innovative medicines, particularly in rare and specialist disease areas, through the acquisition of validated, mid stage development programs.
Financial terms:
Latest news:
